Loss of p16 does not protect against premature ovarian insufficiency caused by alkylating agents.
Alkylating agents
Folliculogenesis
Premature ovarian insufficiency
p16 deficiency
Journal
BMC pregnancy and childbirth
ISSN: 1471-2393
Titre abrégé: BMC Pregnancy Childbirth
Pays: England
ID NLM: 100967799
Informations de publication
Date de publication:
08 Mar 2023
08 Mar 2023
Historique:
received:
23
09
2022
accepted:
28
02
2023
entrez:
8
3
2023
pubmed:
9
3
2023
medline:
11
3
2023
Statut:
epublish
Résumé
Chemical agents such as alkylating agents (AAs) that are commonly used for the treatment of cancer cause great damage to the ovaries, thereby significantly increasing the risk of premature ovarian insufficiency (POI). However, the exact molecules underlying AA-induced POI remain largely obscure. Upregulation of the p16 gene may contribute to the progression of POI. As yet, no in vivo data from p16-deficient (KO) mice are available to demonstrate a critical role of p16 in POI. In the present study, we employed p16 KO mice to investigate whether loss of p16 could protect against POI caused by AAs. WT mice and their p16 KO littermates received a single dose of BUL + CTX to establish an AA-induced POI mouse model. One month later, oestrous cycles were monitored. Three months later, some of the mice were sacrificed to collect sera for measurements of hormone levels and ovaries for measurements of follicle counts, the proliferation and apoptosis of granulosa cells, ovarian stromal fibrosis and vessels. The remaining mice were mated with fertile males for the fertility test. Our results showed that treatment with BUL + CTX significantly disrupted the oestrous cycles, increased the levels of FSH and LH while decreasing the levels of E2 and AMH, decreased the counts of primordial follicles and growing follicles while increasing the counts of atretic follicles, reduced the vascularized area in the ovarian stroma, and decreased fertility. All of these results were comparable between WT and p16 KO mice treated with BUL + CTX. In addition, ovarian fibrosis was not increased significantly in WT and p16 KO mice treated with BUL + CTX. Growing follicles with normal appearance had normally proliferating granulosa cells (without apparent apoptosis). We concluded that genetic ablation of the p16 gene did not attenuate ovarian damage or help preserve the fertility of mice challenged by AAs. This study demonstrated for the first time that p16 is dispensable for AA-induced POI. Our preliminary findings suggest that targeting p16 alone may not preserve the ovarian reserve and fertility of females treated with AAs.
Sections du résumé
BACKGROUND
BACKGROUND
Chemical agents such as alkylating agents (AAs) that are commonly used for the treatment of cancer cause great damage to the ovaries, thereby significantly increasing the risk of premature ovarian insufficiency (POI). However, the exact molecules underlying AA-induced POI remain largely obscure. Upregulation of the p16 gene may contribute to the progression of POI. As yet, no in vivo data from p16-deficient (KO) mice are available to demonstrate a critical role of p16 in POI. In the present study, we employed p16 KO mice to investigate whether loss of p16 could protect against POI caused by AAs.
METHODS
METHODS
WT mice and their p16 KO littermates received a single dose of BUL + CTX to establish an AA-induced POI mouse model. One month later, oestrous cycles were monitored. Three months later, some of the mice were sacrificed to collect sera for measurements of hormone levels and ovaries for measurements of follicle counts, the proliferation and apoptosis of granulosa cells, ovarian stromal fibrosis and vessels. The remaining mice were mated with fertile males for the fertility test.
RESULTS
RESULTS
Our results showed that treatment with BUL + CTX significantly disrupted the oestrous cycles, increased the levels of FSH and LH while decreasing the levels of E2 and AMH, decreased the counts of primordial follicles and growing follicles while increasing the counts of atretic follicles, reduced the vascularized area in the ovarian stroma, and decreased fertility. All of these results were comparable between WT and p16 KO mice treated with BUL + CTX. In addition, ovarian fibrosis was not increased significantly in WT and p16 KO mice treated with BUL + CTX. Growing follicles with normal appearance had normally proliferating granulosa cells (without apparent apoptosis).
CONCLUSION
CONCLUSIONS
We concluded that genetic ablation of the p16 gene did not attenuate ovarian damage or help preserve the fertility of mice challenged by AAs. This study demonstrated for the first time that p16 is dispensable for AA-induced POI. Our preliminary findings suggest that targeting p16 alone may not preserve the ovarian reserve and fertility of females treated with AAs.
Identifiants
pubmed: 36890528
doi: 10.1186/s12884-023-05476-x
pii: 10.1186/s12884-023-05476-x
pmc: PMC9993597
doi:
Substances chimiques
Alkylating Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
151Subventions
Organisme : National Natural Science Foundation of China
ID : 81901436
Organisme : Changzhou Health Committee Funded Young Investigator Training Project
ID : CZQM2020094
Organisme : Key Program of Changzhou Municipal Health Commission
ID : ZD201921
Informations de copyright
© 2023. The Author(s).
Références
Int J Biol Sci. 2019 Mar 1;15(4):870-881
pubmed: 30906217
Nature. 2011 Nov 02;479(7372):232-6
pubmed: 22048312
Life Sci. 2019 Jul 15;229:166-172
pubmed: 31108096
Reproduction. 2016 Sep;152(3):245-260
pubmed: 27491879
Acupunct Med. 2023 Feb;41(1):27-37
pubmed: 35475376
J Clin Invest. 2013 Oct;123(10):4489-501
pubmed: 24091330
J Ovarian Res. 2021 Jan 20;14(1):16
pubmed: 33472700
Aging Cell. 2020 Feb;19(2):e13095
pubmed: 31880094
Cell. 1995 May 5;81(3):323-30
pubmed: 7736585
Am J Transl Res. 2020 Feb 15;12(2):672-683
pubmed: 32194914
Nature. 2006 Sep 28;443(7110):453-7
pubmed: 16957737
Am J Transl Res. 2019 Jun 15;11(6):3850-3861
pubmed: 31312394
J Clin Invest. 2004 Nov;114(9):1299-307
pubmed: 15520862
Climacteric. 2016;19(1):27-36
pubmed: 26576012
Aging (Albany NY). 2019 Jun 10;11(11):3785-3794
pubmed: 31182682
Reprod Biol Endocrinol. 2003 May 07;1:41
pubmed: 12777178
Int J Cancer. 2012 Apr 15;130(8):1715-25
pubmed: 22025288
Cell Death Dis. 2021 Dec 20;13(1):21
pubmed: 34930897
Gynecol Endocrinol. 2018 Apr;34(4):320-326
pubmed: 29073798
Nat Rev Cancer. 2015 Jul;15(7):397-408
pubmed: 26105537
Best Pract Res Clin Obstet Gynaecol. 2012 Jun;26(3):379-90
pubmed: 22281514
Chin J Nat Med. 2021 Oct;19(10):721-731
pubmed: 34688462
Hum Reprod Update. 2019 Nov 5;25(6):673-693
pubmed: 31600388
Fertil Steril. 2018 Oct;110(5):790-793
pubmed: 30316413
Fertil Steril. 2013 Jun;99(7):2045-54.e3
pubmed: 23453120
Cell Metab. 2020 Jul 7;32(1):87-99.e6
pubmed: 32485135
Front Endocrinol (Lausanne). 2021 Aug 12;12:711902
pubmed: 34456868
Oxid Med Cell Longev. 2021 Jul 27;2021:6634718
pubmed: 34367464
Front Cell Dev Biol. 2020 Mar 24;8:176
pubmed: 32266258
Hum Reprod. 2018 Jul 1;33(7):1281-1290
pubmed: 29912328
J Mol Endocrinol. 2018 Apr;60(3):261-271
pubmed: 29437881
Int J Mol Sci. 2012;13(5):5866-5877
pubmed: 22754337
Science. 2002 Jun 21;296(5576):2178-80
pubmed: 12077402
Obstet Gynecol. 2009 Jun;113(6):1355-1363
pubmed: 19461434
Stem Cell Res Ther. 2021 Oct 10;12(1):537
pubmed: 34629095
Cell Physiol Biochem. 2018;51(5):2341-2358
pubmed: 30537739
Indian J Med Res. 2016 Apr;143(4):420-7
pubmed: 27377497
FASEB J. 2019 Jan;33(1):1278-1287
pubmed: 30113879
Am J Respir Cell Mol Biol. 2008 Jul;39(1):7-18
pubmed: 18239191
Commun Biol. 2019 Aug 9;2:307
pubmed: 31428695
Adv Exp Med Biol. 2018;1086:199-215
pubmed: 30232761
Biochem Biophys Res Commun. 2017 Apr 29;486(2):264-269
pubmed: 28286271
Sci Rep. 2021 Feb 25;11(1):4525
pubmed: 33633319
EMBO J. 2017 Aug 1;36(15):2280-2295
pubmed: 28607003
Front Endocrinol (Lausanne). 2022 Mar 07;13:781404
pubmed: 35340329
Cells. 2021 Jun 13;10(6):
pubmed: 34199299
Am J Respir Cell Mol Biol. 2018 Aug;59(2):189-199
pubmed: 29447461
Nature. 2016 Feb 11;530(7589):184-9
pubmed: 26840489
Gene. 2017 Jan 5;596:1-8
pubmed: 27729272